Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations

Tamra Lysaght, Ian Kerridge, Douglas Sipp, Gerard Porter, Benjamin J. Capps

Producción científica: Contribución a una revistaComentario/debaterevisión exhaustiva

20 Citas (Scopus)

Resumen

Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited.

Idioma originalEnglish
Páginas (desde-hasta)647-651
Número de páginas5
PublicaciónCell Stem Cell
Volumen13
N.º6
DOI
EstadoPublished - dic. 5 2013
Publicado de forma externa

Nota bibliográfica

Funding Information:
The research for this article was conducted as part of the “Asian Biopoleis: Biotechnology and Biomedicine as emergent Forms of Life and Practice” Project, funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS).

ASJC Scopus Subject Areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Huella

Profundice en los temas de investigación de 'Oversight for clinical uses of autologous adult stem cells: Lessons from international regulations'. En conjunto forman una huella única.

Citar esto